Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969939 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT04969939 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 120 participants.
The verdict
NCT04969939, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same day. Participants will have to take the study medicine by use of a pre-filled pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show participants how. The study will last for about 26 weeks. Participants will have 17 visits at the clinic with the study doctor. At 4 of the clinic visits participants cannot eat and drink (water is allowed until 2 hours prior to the visit) for 8 hours before the visit.Women: Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period. Women who are able to become pregnant can participate if they agree to use contraception during the study.
Interventions
- DRUG Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
- DRUG Semaglutide 2.4 mg and placebo 2.0 mg
- DRUG Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- DRUG Semaglutide 2.4 mg and placebo 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969939
The ClinicalTrials.gov registry entry for NCT04969939 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide 2.4 mg and NNC0165-1875 2.0 mg is the first listed.
NCT04969939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04969939 about?
NCT04969939 is a clinical study titled "A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity". The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo). Which treatment participants get is decided by chance. Participants will get 2 injections per week, on the same ...
What is the current status of trial NCT04969939?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-07-15. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT04969939?
The interventions under investigation include: Semaglutide 2.4 mg and NNC0165-1875 2.0 mg (DRUG), Semaglutide 2.4 mg and placebo 2.0 mg (DRUG), Semaglutide 2.4 mg and NNC0165-1875 1.0 mg (DRUG), Semaglutide 2.4 mg and placebo 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT04969939?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.